To List Or Not To List; That Is The Question – The FT

Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny.

Related Keywords

United States , , Drug Administration , Trademark Office , Orange Book , Risk Evaluation , Mitigation Strategy , Federal Trade , Listening Session , That Policy Statement , Policy Statement , Commission Act , Hatch Waxman Act , Advisory Opinions , Press Release , First Circuit , Purple Book , Representative Annie Kuster , Senators Maggie , Mike Braun , Patent Integrity , United States Patent , Mondaq , To List Or Not That Is The Question X2013 Ftc Signals Potential For Greater Scrutiny Of Patent Information Submissions Fda , Food , Drugs , Healthcare , Life Sciences , Food And Drugs Law , Intellectual Property , Patent ,